key: cord-0695999-i15sjq3e authors: Ghorbani, Mahdi; Brooks, Bernard R.; Klauda, Jeffery B. title: Exploring dynamics and network analysis of spike glycoprotein of SARS-COV-2 date: 2020-09-28 journal: bioRxiv DOI: 10.1101/2020.09.28.317206 sha: 5e49866ce5c4b7192abf8c20fce2a72c5330792f doc_id: 695999 cord_uid: i15sjq3e The ongoing pandemic caused by coronavirus SARS-COV-2 continues to rage with devastating consequences on human health and global economy. The spike glycoprotein on the surface of coronavirus mediates its entry into host cells and is the target of all current antibody design efforts to neutralize the virus. The glycan shield of the spike helps the virus to evade the human immune response by providing a thick sugar-coated barrier against any antibody. To study the dynamic motion of glycans in the spike protein, we performed microsecond-long MD simulation in two different states that correspond to the receptor binding domain in open or closed conformations. Analysis of this microsecond-long simulation revealed a scissoring motion on the N-terminal domain of neighboring monomers in the spike trimer. Role of multiple glycans in shielding of spike protein in different regions were uncovered by a network analysis, where the high betweenness centrality of glycans at the apex revealed their importance and function in the glycan shield. Microdomains of glycans were identified featuring a high degree of intra-communication in these microdomains. An antibody overlap analysis revealed the glycan microdomains as well as individual glycans that inhibit access to the antibody epitopes on the spike protein. Overall, the results of this study provide detailed understanding of the spike glycan shield, which may be utilized for therapeutic efforts against this crisis. Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has rapidly spread worldwide since early 2020 and has been considered one of the most challenging global health crises within the century. SARS-COV-2 has caused more than 20 million cases and more than 1 million deaths worldwide as of September 2020.(1, 2) Drug and vaccine development are underway and multiple vaccines have entered clinical trials and some of them are in the last stages of development. (3) (4) (5) SARS-COV-2 is a lipid-enveloped single stranded RNA virus belonging to the beta-coronavirus family, which also includes MERS, SARS and bat related coronaviruses. (6) (7) (8) (9) A major characteristic of all coronaviruses is the spike protein (S), which protrudes outward from the viral membrane and plays a key role in the entry of the pathogen into the host cells by binding to human angiotensin converting enzyme-2 (h-ACE2). (6, (10) (11) (12) The structure of each monomer of the trimeric spike protein in SARS-COV-2 ( Figure 1 ) can be divided into two subunits (S1 and S2), which can be cleaved at residues 685-686 (furin cleavage site) by TMPRSS protease after binding to host cell receptor h-ACE2.(12) S1 subunit in S trimer includes a N-terminal domain (NTD) and a receptor binding domain (RBD) that is responsible for binding to h-ACE2.(13) S2 subunit contains fusion peptides (FP), heptad repeats (HR1 and HR2), a transmembrane (TM) and a cytoplasmic domain (CP). The homotrimeric spike protein is highly glycosylated with 22 predicted N-linked glycosylation and 4 O glycosylation sites per monomer, most of which are confirmed by Cryo-EM studies. (14) (15) (16) (17) Glycosylation of proteins plays a crucial role in numerous biological process such as protein folding and evasion of immune response. (18) The receptor binding domain (RBD) of SARS-COV-2 binds to its receptor h-ACE2 with a significantly higher affinity than the earlier SARS coronavirus which is suggested to be the reason for its higher infection rate than SARS-COV in [2002] [2003] . (19) A receptor binding motif (RBM) in RBD makes all the contacts with the receptor by binding its concave surface to the convex exposed surface of h-ACE2. (20) Details of interaction between RBD of SARS-COV-2 and h-ACE2 are studied by us and by other groups, which showed that RBD of SARS-COV-2 binds to h-ACE2 with about 30 kcal/mol higher affinity than SARS-COV RBD. Mutations at critical residues from SARS to SARS-COV-2 RBM are suggested to the be the reason for the higher affinity. (19, 21) Natural mutations at the RBM of SARS-COV-2 have been found in multiple countries, which are not known to be linked with the severity of coronavirus. (22) In an earlier study, we have shown that most of these mutations in RBM do not affect the binding affinity of SARS-COV-2 RBD to h-ACE2 demonstrating the high tolerance of the interface for mutations. Our analysis showed the high contribution of critical residues K417, Q493, Q498 and G502 of RBM in SARS-COV-2 for its high binding affinity. In addition, our alanine scanning of interface residues in nCOV-2019 RBD showed that alanine substitution at some residues such as G502, K417 and L455 can significantly decrease the binding affinity of the complex. (19) The spike protein in SARS-COV-2 is highly glycosylated with 22 N-linked glycosylation sites and 4 O-linked glycosylation sites. (14, 15) Glycosylation of the spike proteins plays a major role in evading the humoral immune system by cloaking the S protein by a thick shield of glycans. (23, 24) For example, the HIV-1 envelope glycoprotein (Env) features about 93 N-linked glycosylation sites with mostly high mannose glycans (Man5-9), which covers most of the surface of the spike protein in HIV-1 and comprises over half its mass. (25) (26) (27) N-linked glycosylation starts with synthesis of precursor oligosaccharides, which are modified to high mannose forms by glucosidases and then trimmed to complex forms in the Golgi by glucosyltransferases for signaling and other glycobiological functions.(28) A higher degree of processing is usually indicative of exposure or accessibility of glycans to enzymes.(25) Dense crowding glycan regions limit the activity of processing enzymes at these locations. In this study, we report the microsecond long MD simulation of all-atom solvated fully glycosylated spike protein embedded in a viral membrane model in both RBD-up or open state (PDB:6VSB)(10) and RBD-down (PDB:6VXX) (13) or closed state. The structure of the two states for glycosylated S protein in viral membrane were taken from the CHARMM-GUI website for this study. (14) Details of modeling different regions were presented in detail by Im and coworkers. (14) Structural changes in the spike protein happens on the order of microsecond timescale, where a scissoring motion is observed between the NTDs in the RBD-up conformation. We have used network analysis and centrality measures in graph theory to pinpoint the structural features of the glycan shield in the context of glycan-glycan interactions as well as binding of antibodies to the spike protein. A modularity algorithm helped us to find glycan microdomains featuring high glycan-glycan interactions with breaches between microdomains for antibodies to bind and neutralize the virus. Dynamical motions of the spike protein: The root-mean-square deviation (RMSD) for each region of the spike protein in RBD-up and RBD-down states are represented in Figure S1 . The stalk region in both RBD-up and RBD-down states show a fluctuating RMSD, which is due to bending motion in this region of spike protein. The tilting in the head of spike is also observed in high resolution cryo-ET images as well as other recent MD studies of glycosylated spike in viral membrane. (29, 30) The bending dynamics in the stalk region is suggested to assist the virus in scanning the cell surface for receptor proteins more efficiently. (30) A snapshot of the open system at 1 μs is represented in Figure 2A , which shows the incline between the head and the stalk domains of spike. The three chains in the spike protein demonstrate various types of motions characterized by different RMSD values ( Figure S2 ). Glycan root-mean-square fluctuation (RMSF) were calculated for heavy atoms in each glycan and then computing the mean and standard deviation for the glycan ( Figure 2B for open and Figure S3 for closed state). Consistently, in all chains, few of the NTD glycans such as N74 show high RMSF, which is due to the high solvent exposure of this glycan in NTD compared to other regions. The glycans near the RBD in chain A (RBD-up), such as N234 and T323 showed less fluctuation than other chains. Figure 3B . In the open state, NTD of chain B goes toward the center of apex. The distribution of distance between the center of apex and each NTD is shown in Figure S4C . In the RBD-down state, PC-1 shows the motion in RBD of chain A toward the open conformation ( Figure S4B ). The simulation for RBD-down states was separated into two clusters and distribution of the distance between center of mass of RBD and the apex center was calculated for all the chains in both clusters. A clear separation is observed where RBD of chain A is more distant from the apex center in the second cluster ( Figure 3D ). A network analysis was carried out on the glycan shield of the spike protein in both RBD-up and RBD-down states to find the glycans that are most important for an effective shield. This approach has recently been applied to the glycan shield of HIV-1 spike protein. (32, 33) In the glycan network, each glycan represents a node in the graph and two nodes are connected by an edge if the glycans have a distance less than 50 Å in the starting structure. Edges are weighted by the normalized absolute value of non-bonded interaction energy (vdw+electrostatic) between each pair of glycans. A network was built for the whole simulation time in both RBD-up and -down states. All network analysis was performed in networkx and graph visualizations were done using Gephi. (34, 35) The adjacency matrix for these two networks are calculated ( Figure S5 ). Two centrality measurements in graph theory were utilized to analyze the network of glycans. Betweenness centrality quantifies the number of times a node acts as a bridge along the shortest path connecting every two nodes in the graph and is an important indicator of the influence of the node within the network. Eigenvector centrality measures the node's importance in the network by considering the importance of the neighbors of that node. If the node is connected to many other nodes that are themselves well connected, that node is assigned a high eigenvector centrality score ( Figure 5 ). Understanding the structure and dynamics of glycan shield in the spike protein of SARS-COV-2 is an indispensable requirement for any antibody and vaccine design endeavors. (23, 37, 38) To this end, we have performed MD simulations of fully glycosylated spike protein of SARS-COV-2 in both open and closed states. Analysis of dynamics for 1 μs trajectories showed a tilting motion in the stalk region, which was also demonstrated with experimental cryo-ET images (29, 30) and suggested to aid the virus with screening the host cells for receptor proteins (Figure 2A ). Glycan motions were characterized by RMSF ( Figures 2B and S3 ), which showed higher values for stalk glycans demonstrating the high shielding potential of this normally solvent-exposed region. Figure 7A ). The RBM of chain A also showed the highest SASA among other epitopes on spike protein which shows its great potential for antibody design strategies. NTD-binder antibodies can also bind to epitopes on the NTD of spike protein. These antibodies showed high number of clashes with glycans N74 and N149 of the respective monomer that they bind. The glycans on the surface of spike protein exert a collective behavior, which is an important property that needs to be considered in the context of vaccine and antibody design. Table S2 . (15, 16) GROMACS(44) software was used for molecular dynamics (MD) simulation. Energy minimization was performed in 5000 steps using the steepest descent algorithm. A LINCS algorithm in all steps constrained the bonds containing hydrogen atoms. Equilibration was performed with a standard 6-step equilibration scripts from CHARMM-GUI with restraints on protein, lipid and glycan atoms. (45) For the first three steps of equilibration, each step included 125 ps using Berendsen thermostat at temperature 310.15 K and a coupling constant of 1 ps. (46) In the last 4 equilibration steps a Berendsen barostat(47) was used to maintain the pressure at 1 bar. For the production step, all restraints were removed, and the system was simulated under a NPT ensemble using the Parrinello-Rahman barostat(48) with a compressibility of 4.5 × 10 −5 bar −1 and a coupling constant of 5 ps. The temperature was maintained at 310 K using a Nosé-Hoover thermostat with a temperature coupling constant of 1 ps. (49) The production run lasted 1μs for each system (RBD-up and RBD-down) with a 2 fs timestep and the particle-mesh Ewald (PME)(50) for long range electrostatic interactions using GROMACS 2018.3 package. (44) Solvent accessible surface area (SASA): SASA was calculated using VMD(51) with a probe radius of 2 Å which represents the hypervariable region of antibodies.(31) Multiple regions were chosen for SASA calculation: RBM (residues 440 to 508). RBD (residues of RBD away from RBM Glycan-antibody overlap analysis: Antibodies that bind and neutralize spike protein are divided into three categories(39): antibodies that bind to the exposed part of RBD (RBM-binder), antibodies that bind to epitopes away from the RBM in RBD or RBD-binder and antibodies that bind to epitopes on NTD (NTDbinder) A pneumonia outbreak associated with a new coronavirus of probable bat origin A novel coronavirus from patients with pneumonia in China COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): a systematic review Structural and functional basis of SARS-CoV-2 entry by using human ACE2 Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging microbes & infections 9 Origin and evolution of pathogenic coronaviruses Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Characterisation of the transcriptome and proteome of SARS-CoV-2 using direct RNA sequencing and tandem mass spectrometry reveals evidence for a cell passage induced in-frame deletion in the spike glycoprotein that removes the furin-like cleavage site Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein Modeling and Simulation of a Fully-glycosylated Full-length SARS-CoV-2 Spike Protein in a Viral Membrane Site-specific glycan analysis of the SARS-CoV-2 spike Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2. bioRxiv Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor. bioRxiv Glycosylation in health and disease Critical Sequence Hot-spots for Binding of nCOV-2019 to ACE2 as Evaluated by Molecular Simulations Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Is the Rigidity of SARS-CoV-2 Spike Receptor-Binding Motif the Hallmark for Its Enhanced Infectivity? Insights from All-Atoms Simulations Buckland-Merrett, Data, disease and diplomacy: GISAID's innovative contribution to global health Vulnerabilities in coronavirus glycan shields despite extensive glycosylation Exploitation of glycosylation in enveloped virus pathobiology Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G Quantification of the impact of the HIV-1-glycan shield on antibody elicitation Structure and immune recognition of the HIV glycan shield Effects of N-glycosylation on protein conformation and dynamics: Protein Data Bank analysis and molecular dynamics simulation study Map of SARS-CoV-2 spike epitopes not shielded by glycans In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein Microsecond dynamics and network analysis of the HIV-1 SOSIP Env trimer reveal collective behavior and conserved microdomains of the glycan shield Quantification of the Resilience and Vulnerability of HIV-1 Native Glycan Shield at Atomistic Detail Exploring network structure, dynamics, and function using NetworkX. (Los Alamos National Lab.(LANL) Gephi: an open source software for exploring and manipulating networks Fast unfolding of communities in large networks A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike. bioRxiv Glycans on the SARS-CoV-2 spike control the receptor binding domain conformation Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ, ψ and side-chain χ1 and χ2 dihedral angles Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers CHARMM-GUI: a web-based graphical user interface for CHARMM On the Berendsen thermostat Pressure coupling/barostats Polymorphic transitions in single crystals: A new molecular dynamics method The nose-hoover thermostat Particle mesh Ewald: An N⋅ log (N) method for Ewald sums in large systems VMD: visual molecular dynamics A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 Structural and functional analysis of a potent sarbecovirus neutralizing antibody A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2 This work was partially-supported by National Heart, Lung and Blood institute (NHLBI) at the National Institute of Health (NIH) for BRB and MG; in addition it was partially supported by the National Science Additional information in forms of tables and graphs on glycan types, membrane composition, RMSD and RMSF, other network analysis results and details of antibody overlap analysis are presented in the SI section.